Expression of RHBDD1 gene in patients with chronic myeloid leukemia and its clinical significance.
10.7534/j.issn.1009-2137.2013.01.003
- Author:
Ya-Ni LIN
1
;
Fu-Min GUI
;
Hui SHEN
;
Fang WANG
;
Zeng CAO
;
Qing-Hua LI
;
Jian-Xiang WANG
;
Tian-Xiang PANG
Author Information
1. Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
- Publication Type:Journal Article
- MeSH:
Bone Marrow Cells;
metabolism;
pathology;
Case-Control Studies;
Female;
Gene Expression;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
genetics;
metabolism;
pathology;
Male;
Middle Aged;
Serine Endopeptidases;
genetics;
metabolism
- From:
Journal of Experimental Hematology
2013;21(1):12-15
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the expression of RHBDD1 gene in patients with chronic myeloid leukemia (CML) and explore its clinical significance. The relative expression levels of RHBDD1 in bone marrow mononuclear cells of healthy controls and CML patients were detected by using real time PCR. The results showed that the expression level of RHBDD1 in CML patients was significantly higher than that in healthy controls. The expression level of RHBDD1 in CML patients with negative BCR/ABL p210 was remarkably higher than that in patients with positive BCR/ABL p210. In patients ≥ 50 years old RHBDD1 expression was lower than the patients < 50 years old. There were no significant relation of RHBDD1 expression with sex of patients. It is concluded that RHBDD1 gene may be involved in the pathogenesis and progression of CML, particularly reflects in the pathogenesis of the patients with negative BCR/ABL p210.
